Celgene Moves Into Solid Tumors With $2.9 Billion Abraxis Acquisition
Celgene is acquiring Abraxane developer Abraxis Biosciences and planning an aggressive development and marketing push for the novel nanoparticle formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015
You may also be interested in...
The big biotech enters a collaboration in cancer immunotherapy and inflammation with Xencor, acquires Dutch biotech Dezima, and licenses a c-MET inhibitor to NantWorks. Also, Sun Pharma steps in to buy InSite Vision, which had been targeted by QLT.
Celgene is launching Revlimid in China and will go it alone without a local partner. Many consider the move curious, but some say companies such as Roche paved the way for Celgene.
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.